Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exogenous Ketone Esters for Refractory Status Epilepticus in Children
NCT05674552Phase 3Recruiting
- Sponsor
- Sohag University
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in Generalized Convulsive Status Epilepticus (GCSE) (2 arms), sponsored by Sohag University. Primary endpoint: Proportion of patients achieving electroclinical cessation of seizures at 60 minutes. Started Jan 2023; status: recruiting.
02
Drugs
(R)-3-hydroxybutyl (R)-3-hydroxybutyrate
03
Conditions
Generalized Convulsive Status Epilepticus (GCSE)
Beyond the preview
Go deeper on NCT05674552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674552.